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A B S T R A C T   
Antibiotic resistance is increasing even in ocular pathogens, therefore the interest towards antiseptics in 
Ophthalmology is growing. The aim of this study was to analyze the in vitro antimicrobial efficacy and the in 
vitro effects of an ophthalmic formulation containing hexamidine diisethionate 0.05%, polyhexamethylene 
biguanide (PHMB) 0.0001% disodium edetate (EDTA) 0.01%, dexpanthenol 5% and polyvinyl alcohol 1.25% 
(Keratosept, Bruschettini, Genova, Italy) on cultured human corneal and conjunctival cells. The in vitro anti-
microbial activity was tested on Staphylococcus aureus, Methicillin-Resistant Staphylococcus aureus (MRSA), 
Pseudomonas aeruginosa, Streptococcus pneumoniae, Streptococcus pyogenes and Streptococcus mitis. For each mi-
crobial strain 10 μL of a 0.5 MacFarland standardized bacterial inoculum were incubated at 25 ◦C with 100 μL of 
ophthalmic solution for up to 6 h. After different periods of time, samples were inoculated on blood agar with 5% 
sheep blood. Moreover, a 0.5 MacFarland bacterial inoculum was seeded in triplicate on Mueller-Hinton Agar or 
on Mueller-Hinton Fastidious Agar; then a cellulose disc soaked with 50 μL of ophthalmic solution was applied on 
the surface of agar and plates were incubated for 18 h at 37 ◦C, in order to evaluate the inhibition of bacterial 
growth around the disc. Human corneal and conjunctival epithelial cells in vitro were incubated for 5, 10 and 15 
min with Keratosept or its components. The cytotoxicity was assessed through the release of cytoplasmic enzyme 
lactate dehydrogenase (LDH) into the medium immediately after exposure to the drugs; the 3-(4,5-dimethylth-
iazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay was performed to evaluate the metabolic cell activity. 
Our results show that Keratosept ophthalmic solution gave an average logarithmic (log) reduction of bacterial 
load of 2.14 ± 0.35 within 6 h of exposure (p-value < 0.05 versus control saline solution). On agar plates, all 
microbial strains, excluding P. Aeruginosa, showed an inhibition zone of growth around the Keratosept-soaked 
discs. Keratosept and its components after 5 and 10 min did not show any cytotoxic effect on cultured corneal 
and conjunctival cells, and only after 15 min a significant reduction of cell viability and an increase of cyto-
toxicity compared to control (vehicle) was seen; dexpanthenol 5% and polyvinyl alcohol accelerated the 
wounding of corneal cells in vitro. In conclusion, Keratosept showed good antimicrobial activity on the tested 
strains; the ophthalmic solution and its components were safe and non-toxic for the corneal and conjunctival 
epithelial cells for 5 and 10 min at the concentrations analyzed, and dexpanthenol 5% and polyvinyl alcohol 
promoted the wounding of corneal cells.   
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1. Introduction 
Antimicrobial resistance to antibiotics is one of the biggest public 
health challenges of our time and it has been continuously increasing in 
recent years, even in ocular pathogens (Asbell and DeCory, 2018; Ber-
tino, 2009; Holland et al., 2014). As in all human infections, the rise of 
bacterial resistance can also be of concern in ophthalmology, leading to 
unsuccessful treatment of sight-threatening infections (Asbell and 
DeCory, 2018; Bertino, 2009; Holland et al., 2014). 
Since the overuse of antibiotics in the treatment of ocular infectious 
diseases has led to the appearance of multidrug-resistant bacterial 
strains (Asbell and DeCory, 2018), the interest towards antiseptics is 
growing. In ophthalmology, the role of topical antibiotics in the pro-
phylaxis of post-surgical endophthalmitis, especially in intravitreal in-
jections, is under debate because their perioperative use can increase the 
resistance of conjunctival flora but has no proven added effectiveness in 
preventing endophthalmitis if combined with povidone iodine antisepsis 
(Grzybowski et al., 2017). 
Moreover, due to their wide spectrum of activity (multi-drug resis-
tant bacteria, methicillin-resistant staphylococcus aureus, viruses, pro-
tozoa, fungi) (Grzybowski et al., 2018; Kaehn, 2010; Maycock and 
Jayaswal, 2016), and the few reports on reduced microbial susceptibility 
which currently only concern chlorhexidine (Horner et al., 2012; Kampf, 
2016), the use of antiseptics has been proposed for the treatment of viral 
conjunctivitis, mild bacterial conjunctivitis, or even more severe in-
fections (such as keratitis) in developing countries, where the avail-
ability of antibiotics is often limited by costs (Grzybowski et al., 2018; 
Isenberg et al., 2017). Regarding Acanthamoeba keratitis, the only 
available treatment are the antiseptics biguanides (PHMB 0.02%, and 
chlorhexidine 0.02%) and diamidines (hexamidine 0.1% or prop-
amidine 0.1%) (Carrijo-Carvalho et al., 2017; Maycock and Jayaswal, 
2016). 
However, antiseptics may be toxic for the ocular surface epithelia, 
leading to corneal epithelial defects or damage, especially at high con-
centrations (Shibata et al., 2014). Therefore, there is an increasing in-
terest in topical formulations containing antiseptics with a wide 
antimicrobial spectrum, but with a lower tendency to damage the ocular 
surface. Recently, an ophthalmic solution containing antiseptics, such as 
hexamidine diisethionate 0.05%, PHMB 0.0001%, disodium edetate 
(EDTA) 0.01%, and healing agents, such as dexpanthenol (D-panthenol) 
5% and polyvinyl alcohol 1.25%, has been launched on the market in 
Italy (Keratosept, Bruschettini, Genova, Italy). The purposes of our study 
were to evaluate the antimicrobial activity of this product on isolates of 
Staphylococcus aureus, Methicillin-Resistant Staphylococcus aureus 
(MRSA), Pseudomonas aeruginosa, Streptococcus pneumoniae, Strepto-
coccus pyogenes and Streptococcus mitis, that are among the most frequent 
causes of ocular infections (Asbell and DeCory, 2018; Garg et al., 2017; 
Green et al., 2008; Han et al., 1996; Teweldemedhin et al., 2017) and to 
analyze in vitro the effects of this solution and of its components on 
cultured human corneal and conjunctival cells. 
2. Materials and methods 
2.1. In vitro antimicrobial activity of the ophthalmic solution 
The antimicrobial activity of the ophthalmic solution was evaluated 
using a modified protocol from the International Organization for 
Standardization- ISO 14729 guidelines (International Organization for 
Standardization, 2001). 
Staphylococcus aureus, Methicillin-Resistant Staphylococcus aureus 
(MRSA), Pseudomonas aeruginosa, Streptococcus pneumoniae, Strepto-
coccus pyogenes and Streptococcus mitis (of the Viridans Group Strepto-
cocci, VGS) were used in this study. All the microbial strains were 
obtained from the collection at the microbiology laboratory of the 
University Hospital “Città della Salute e della Scienza di Torino”, Turin – 
Italy. The isolates of MRSA were resistant to fluoroquinolones and 
aminoglycosides, while the other bacteria were susceptible to all anti-
microbial agents routinely tested. For each species 5 different isolates in 
triplicates were tested. 
For each microbial strain a 0.5 MacFarland standardized bacterial 
inoculum (1.5 × 108 colony-forming unit/mL) was prepared in sterile 
phosphate buffered saline solution, then 10 μL of inoculum were incu-
bated at 25 ◦C with 100 μL of ophthalmic solution for up to 6 h. At the 
defined time points of 10, 30 and 45 min, 1, 2, 4, 6 h, 10 μL of solution 
were removed and added to 100 μL of neutralizing broth (Becton 
Dickinson, USA); then, 10 μL of samples were inoculated on blood agar 
with 5% sheep blood (Becton Dickinson, USA), plating each sample in 
triplicate. The numbers of viable bacteria in the samples were deter-
mined by plate counts of colony-forming units (CFUs) after serial di-
lutions following an overnight incubation at 37 ◦C. A sterile isotonic 
solution, without antiseptics, was used as a control. 
In order to evaluate the ability of bacteria to grow on agar-nutrient 
plates in the presence of ophthalmic solution, a 0.5 MacFarland bacte-
rial inoculum was seeded in triplicate on Mueller-Hinton Agar (Becton 
Dickinson, USA) for non-fastidious bacteria (S. aureus, MRSA, 
P. aeruginosa) and on Mueller-Hinton Fastidious Agar (Becton Dickinson, 
USA) for fastidious bacteria (S. pneumoniae, S. pyogenes and S. mitis). 
Then a cellulose disc soaked with 50 μL of ophthalmic solution was 
applied on the surface of the agar and plates were incubated for 18 h at 
37 ◦C, in order to evaluate the inhibition of bacterial growth around the 
disc. 
2.1.1. Statistical analysis 
Data are presented as log reduction in CFU per mL (Log CFU/mL) for 
each microorganism at each exposure time. The Log CFU/mL reduction 
of control was obtained from the overall mean of all tested strains. 
Differences between Log reductions were analyzed by using a two-tailed 
Student t-test and a p-value < 0.05 was considered significant. 
2.2. In vitro effects of the ophthalmic solution and its components on 
cultured human corneal and conjunctival cells 
2.2.1. Materials 
Human corneal epithelial cells (HCE-2) [50B1] (ATCC CRL-11135) 
were purchased from ATCC company (American Type Culture Collec-
tion, PO Box 1549 Manassas, VA, 20108, USA). Human conjunctival 
epithelial cells (HConEC) and corneal epithelium cell medium consisting 
of the basal medium and corneal epithelial cell growth supplement 
(CEpiCGS) were provided by Innoprot (Derio, Bizkaia, Spain). Kerati-
nocyte serum-free medium, bovine pituitary extract (BPE) and 
epidermal growth factor (EGF) were purchased from Gibco-BRL (San 
Giuliano Milanese, MI, Italy). Hydrocortisone, insulin, fibronectin, 
bovine collagen type I and bovine serum albumin (BSA) penicillin/ 
streptomycin (P/S), bovine fetal serum and poly-L-lysine, benzalkonium 
chloride (BAK) and 3-(4,5-dimethylthiazol-2-yl)-25-diphenylte-
trazolium bromide (MTT) were obtained from Sigma (St Louis, MO, 
USA). The Cytotoxicity detection kit (lactate dehydrogenase, LDH) was 
obtained from Roche Diagnostics (Basel, Switzerland). 
Keratosept and all its constituents were a kind gift from Bruschettini 
srl (Genova, Italy). 
2.2.2. Human corneal epithelial cells (HCE-2) 
Human corneal epithelial cells (HCE-2) were kept in culture in ker-
atinocyte serum-free medium supplemented with 0.05 mg/mL BPE, 5 
ng/mL EGF, 500 ng/mL hydrocortisone and 0.005 mg/mL insulin. The 
cells were incubated at 37 ◦C in an atmosphere of humidified air and 5% 
CO2, and then seeded on 75 cm2 flasks precoated with a mixture of 0.01 
mg/mL fibronectin, 0.03 mg/mL bovine collagen type I and 0.01 mg/mL 
BSA. 
The keratinocyte serum-free medium was changed twice a week. 
Once confluence was reached, the cells were split with a 1:3 proportion 
into other flasks previously treated. 
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2.2.3. Human conjunctival epithelial cells (HConEC) 
Human conjunctival epithelial cells (HConEC) provided by Innoprot 
are isolated from human conjunctiva. The cells were kept in culture in 
conjunctival epithelial cell medium consisting of the basal medium with 
the addition of the conjunctival epithelial cell growth supplement 
(CEpiCGS), penicillin/streptomycin (P/S) and bovine fetal serum, in an 
atmosphere of humidified air and 5% CO2 at 37 ◦C. The cells were plated 
in 75 cm2 flasks previously treated for 1 h with a solution of poly-L- 
lysine 1:10 in PBS. The culture medium was changed twice a week. 
Once the confluence was reached, the cells were split with a 1:3 pro-
portion in other previously treated flasks. 
2.2.4. Incubation with drugs 
Human corneal and conjunctival epithelial cells were resuspended 
and seeded into 24-well plates (approximately 4 × 10− 4 cells/cm2). 
When they reached approximately a 70–80% confluence, the culture 
medium was removed and the cells were exposed to Keratosept or to all 
the individual constituents of the formulation (polyvinyl alcohol 1.25%, 
D-panthenol 5%, hexamidine diisethionate 0.05%, PHMB 0.0001%, 
methyl sulfone dimethyl sulfone 1.25%, EDTA 0,01%) dissolved in the 
Keratosept vehicle, which consists in a buffer solution (potassium 
phosphate 0.04%, dibasic sodium phosphate 0.2% and H20). The vehicle 
was used as positive control and BAK 0.01% for 2 h was used as negative 
control for maximum cell death. 
Corneal and conjunctival epithelial cells were incubated with drugs 
in different concentrations (dilution 1:1 and 1:10) and for 3 different 
periods (5, 10 and 15 min). 
2.2.5. Analysis of cell viability: MTT assay 
The viability of the conjunctival and corneal epithelial cells exposed 
for 3 different periods (5, 10, 15 min) and in different dilutions (1:1 and 
1:10) to all the individual constituents of Keratosept and to the complete 
formulation, was evaluated by MTT assay. 
The cells were seeded in 24-well plates and maintained in culture. All 
the drugs were incubated in different concentrations for different pe-
riods in the vehicle. Part of the medium of each well was taken and 
stored for the LDH assay. The cells were incubated with MTT at a con-
centration of 1 mg/mL (Piazzini et al., 2019). After removing the MTT 
solution, dymethyl sulfoxide (DMSO) was added to the wells to dissolve 
the formation, and the absorbance of MTT was read at 550 and 690 nm. 
The vehicle was used as a positive control. Cell viability was expressed 
as a percentage of the cells incubated only in the vehicle in the corre-
sponding exposure period. 
2.2.6. Evaluation of cell death: LDH assay 
Damage in the human corneal and conjunctival epithelial cells was 
quantitatively evaluated by measuring the amount of the soluble cyto-
solic enzyme LDH released from injured cells into the extracellular fluid, 
5,10 and 15 min after exposure to the drugs, using the LDH kit, as 
previously described for mix cortical cells (Landucci et al., 2019). 
The LDH level corresponding to complete cell death was determined 
for each experiment by assaying sister cultures exposed to BAK 0.01% 
for 2 h. Background LDH release was determined in control cultures not 
exposed to drugs, and was subtracted from all experimental values. The 
resulting values correlated linearly with the degree of cell loss estimated 
at the observation of cultures under phase-contrast optics. 
2.2.7. Analysis of corneal wound healing 
Human corneal epithelial cells were used for re-epithelialization 
studies. Double insert wells of biocompatible silicone (width x length 
x height = 8.4 mm × 8.4 mm x 5 mm), with a growth size of 0.22 cm2 
and a 70 μL plating volume for each well, from Ibidi (Lochhamer Schlag, 
Gräfelfing, Germany) were used for all epithelialization tests. The cells 
were seeded on the inserts and after 24 h the inserts were removed 
leaving a space of 420 μm between the two layers of cells, an identical 
size for each experiment. Then, D-panthenol 5% and polyvinyl alcohol 
1.25% were dissolved in the culture medium and corneal cell mono-
layers were incubated for 24 and 48 h to test re-epithelialization in 
comparison with cell inserts exposed to the culture medium alone 
(control). The extent of healing was evaluated qualitatively in a blind 
fashion and photographed by an inverted phase-contrast microscope 
(Olympus IX-50; Solent Scientific, Segensworth, UK) at 10X 
magnification. 
2.2.8. Statistical analysis 
Data are presented as mean ± standard error of the mean (SEM) of n. 
experiments. The statistical significance of differences in MTT and LDH 
release were analyzed using one-way ANOVA with Dunnett’s post-hoc 
test for multiple comparisons. All statistical calculations were per-
formed using GraphPad Prism version 5 for Windows (GraphPad Soft-
ware, San Diego, CA, USA). A p-value < 0.05 was considered significant. 
3. Results 
3.1. In vitro antimicrobial activity of the ophthalmic solution 
The Keratosept ophthalmic solution showed an antiseptic spectrum 
of activity and gave an average log reduction of 2.14 ± 0.35 within 6 h of 
exposure, significantly higher than the control solution (p-value < 0.05), 
although individual log reductions varied between microorganisms 
(Fig. 1). Log reductions of the fastidious species (Streptococcus pneumo-
niae, Streptococcus mitis and Streptococcus pyogenes) were significantly 
marked within 2 h of exposure to the ophthalmic solution (p-value <
0.05 vs control for all comparisons). Especially for Streptococcus pneu-
moniae and Streptococcus mitis a log reduction of 2.40 ± 0.39 and 2.00 ±
0.87 occurred at 30 min of exposure (Fig. 1). 
Of the non-fastidious species (Staphylococcus aureus, MRSA and 
Pseudomonas aeruginosa), Staphylococcus aureus showed a log reduction 
of 1.66 ± 0.26 after 6 h of exposure to the ophthalmic solution, while for 
MRSA the log reduction was 2.32 ± 0.59. However, the difference be-
tween the two strains was not significant (p-value > 0.05). The log 
reduction was especially marked for Pseudomonas aeruginosa within 45 
min of exposure (2.08 ± 0.34). 
All the microbial strains, except P. aeruginosa, after an overnight 
incubation on agar plates, showed an inhibition zone of growth around 
the Keratosept-soaked discs, with a mean diameter of 17.27 ± 4.37 mm 
(Table 1). 
3.2. Evaluation of the effects of Keratosept and its constituents on corneal 
and conjunctival epithelial cells using LDH and MTT assay 
Using LDH as a quantitative cytotoxicity index, we examined the 
extent of human corneal epithelial cell death. The maximum degree of 
cell death was produced in our culture system by incubation for 2 h with 
0.01% BAK, which produced a maximum release of LDH. 
After 5 and 10 min of incubation, Keratosept and all its components 
displayed negligible corneal cell death (Fig. 2 A, B); Keratosept and some 
of its components, such as EDTA and methyl sulfone dimethyl sulfone, 
began to be toxic only after 15 min (Fig. 2 C). 
The viability of corneal epithelial cells after exposure to Keratosept 
and its components is shown in Fig. 3. After 5 and 10 min exposure no 
significant changes in cell viability measured by MTT assay were 
detected except for BAK 0.01% (Fig. 3 A, B). However, after 15 min 
Keratosept, EDTA and methyl sulfone dimethyl sulfone significantly 
decreased the cell viability to 21%, 28% and 25% of the vehicle value, 
respectively. (Fig. 3 C). 
We also tested the Keratosept formulation on the human conjunctival 
epithelial cells. 
At all the 3 incubation periods, Keratosept and all its components 
caused negligible cell death, like the vehicle (Fig. 4 A, B, C). 
Regarding the MTT assay, we observed a reduction of cell viability 
with Keratosept at 10 min and with Keratosept, hexamidine 
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diisethionate and EDTA at 15 min. Conversely, the exposure for 5 min to 
polyvinyl alcohol and D-panthenol induced a significant increase in the 
level of MTT assay (Fig. 5). 
Finally, we tested Keratosept and all its components diluted 1:10 on 
human corneal (Fig. 6 A, B) and on conjunctival (Fig. 6 C, D) epithelial 
cells for 15 min. Keratosept and all its single components showed no 
signs of toxicity at dilution 1:10 in comparison with BAK 0.01% (after 2 
h of exposure) (Fig. 6, A and C) and showed no alteration of cell viability 
(Fig. 6, B and D). 
3.3. Corneal wound healing 
In human corneal epithelial cells incubated only in culture medium 
(the control), the analysis of the corneal wound area revealed that the 
wound was completely covered after 48 h; when the cells were exposed 
to a combination of polyvinyl alcohol 1.25% and D-panthenol 5%, the 
gap was completely covered in 24 h (Fig. 7). 
4. Discussion 
Increasing trends in antibiotic resistance in ocular infections, espe-
cially widespread fluoroquinolone non-susceptibility (Asbell and 
DeCory, 2018; Bertino, 2009; Holland et al., 2014), have enhanced the 
role of antiseptics in the prevention of infection after ocular surgery 
(Grzybowski et al., 2017). Nowadays, povidone-iodine (PVI) and 
chlorhexidine represent the elective antiseptics in ophthalmology. 
However, a reduced susceptibility to chlorhexidine of MRSA and other 
staphylococci was reported by Horner et al. (2012), discouraging its 
indiscriminate use in the absence of efficacy data. For these reasons, 
Fig. 1. Antimicrobial activity of Keratosept ophthalmic solution expressed as log CFU/mL reduction in relationship to exposure time. CFU = colony-forming unit, 
MRSA = Methicillin-resistant Staphylococcus aureus, min = minutes, h = hours. 
Table 1 
Microbial growth on agar plates in presence of Keratosept ophthalmic 
solution.  
Organism Growth inhibition at 18 h 
Staphylococcus aureus Presence of inhibition 
MRSA Presence of inhibition 
Pseudomonas aeruginosa Absence of inhibition 
Streptoccocus pneumoniae Presence of inhibition 
Streptococcus mitis Presence of inhibition 
Streptococcus pyogenes Presence of inhibition 
MRSA: Methicillin-Resistant Staphylococcus aureus. 
Fig. 2. Evaluation of lactate dehydrogenase (LDH) release in the human corneal epithelial cells (HCE-2) after (A) 5 min, (B) 10 min or (C) 15 min of incubation with 
Keratosept or its components. Data are expressed as percentage of the maximum degree of cell death (incubation of cells for 2 h with 0.01% of BAK); they represent 
the mean ± standard error of the mean of at least 3 experiments performed in triplicate. *p < 0.05 vs Veh; **p < 0.01 vs Veh; Veh = vehicle, EDTA = disodium 
edetate, BAK = benzalkonium chloride, D-Panthenol = Dexpanthenol. 
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Fig. 3. Evaluation of MTT assay in the human corneal epithelial cells (HCE-2) after (A) 5 min, (B) 10 min or (C) 15 min of incubation with Keratosept or its 
components. Data are expressed as percentage of the maximum cell viability (Veh); they represent the mean ± standard error of the mean of at least 3 experiments 
performed in triplicate. *p < 0.05 vs Veh; **p < 0.01 vs Veh; Veh = vehicle, EDTA = disodium edetate, BAK = benzalkonium chloride, D-Panthenol = Dexpanthenol. 
Fig. 4. Evaluation of lactate dehydrogenase (LDH) release in the human conjunctival epithelial cells (HConEC) after (A) 5 min, (B) 10 min or (C) 15 min of in-
cubation with Keratosept or its components. Data are expressed as percentage of the maximum degree of cell death (incubation of cells for 2 h with 0.01% of BAK); 
they represent the mean ± standard error of the mean of at least 3 experiments performed in triplicate. **p < 0.01 vs Veh; Veh = vehicle, EDTA = disodium edetate, 
BAK = benzalkonium chloride, D-Panthenol = Dexpanthenol. 
Fig. 5. Evaluation of MTT assay in the human conjunctival epithelial cells (HConEC) after (A) 5 min, (B) 10 min or (C) 15 min of incubation with Keratosept or its 
components. Data are expressed as percentage of the maximum cell viability (Veh); they represent the mean ± standard error of the mean of at least 3 experiments 
performed in triplicate. *p < 0.05 vs Veh; **p < 0.01 vs Veh; Veh = vehicle, EDTA = disodium edetate, BAK = benzalkonium chloride, D-Panthenol = Dexpanthenol. 
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recently, several antiseptic-based ophthalmic formulations have been 
released into the market. 
The ophthalmic solution tested in this study contains 3 antiseptics: 
PHMB 0.0001%, hexamidine diisethionate 0.05% and EDTA 0.01%. 
There are few studies on the antimicrobial activity in vitro and in vivo 
and the safety of PHMB, as reported by Fjeld and Lingaas (2016). 
Interestingly, a single study (Hansmann et al., 2004) evaluated the use of 
PHMB as a preoperative antiseptic for cataract surgery, showing a 
reduction of the conjunctival flora. Regarding hexamidine diisethionate, 
alone or in combination with PHMB, different studies have evaluated 
the efficacy of the compound at a concentration of 0.1% for the treat-
ment of Acanthamoeba keratitis (Brasseur et al., 1994; Carrijo-Carvalho 
et al., 2017; Maycock and Jayaswal, 2016; Perrine et al., 1995), while 
EDTA showed good efficacy as an antibiofilm agent when used 
stand-alone or in combination with other antimicrobials (Finnegan and 
Percival, 2015). However, the antiseptic activity of these compounds 
needs to be better assessed, also because, to our knowledge, no stan-
dardized guidelines (EN, ISO) for the evaluation of the antimicrobial 
activity of ophthalmic solutions exist. 
In our study, the combined effect of these compounds caused a 
reduction of the bacterial load of 2.14 log within 6 h of exposure to the 
ophthalmic solution, especially for Fastidious bacteria (S. pneumonia, S. 
mitis and S. pyogenes). According to Pinna et al. (2020), the Keratosept 
ophthalmic solution showed, using a qualitative method, an antimi-
crobial activity in vitro against different microorganisms. However, in 
our study, we have performed a quantitative analysis during an obser-
vational period of 6 h and we considered 100 μL of ophthalmic solution, 
which is equivalent to approximately 2 drops; for this reason we 
observed, differently from Pinna et al. (2020), who tested a higher 
volume (990 μL) of Keratosept, a slower reduction of bacterial growth 
during the analysis period. Moreover, when tested on the surface of solid 
agar medium, the ophthalmic solution caused inhibition of the microbial 
growth. Only for P. aeruginosa was no inhibition observed: indeed, on a 
solid medium this microorganism is able to form robust biofilms (Lee 
and Yoon, 2017) and this ability is well-known for the corneal surface 
and contact lenses as well (Zegans et al., 2002). 
Further in vitro and clinical studies are necessary to confirm the 
antimicrobial efficacy of this solution against different microorganisms, 
as well as bacterial and fungal biofilms. 
Antiseptics such as povidone-iodine may induce cytotoxic effects on 
the ocular surface epithelial cells, and punctate corneal epithelial 
keratitis, epithelial defects and conjunctival irritation, as confirmed by 
in vivo studies (Koerner et al., 2018), especially at high concentrations. 
Therefore, it is important to assess the potentially harmful effects of 
antiseptic-containing solutions on the ocular surface. 
To our knowledge, no studies have been published on the in vitro 
Fig. 6. Evaluation of lactate dehydrogenase (LDH) release in human corneal (HCE-2) (A) and conjunctival (HConEC) (B) epithelial cells and cell viability by MTT 
assay in corneal (B) or conjunctival (D) cells after 15 min of incubation with Keratosept or its components at a 1:10 dilution. Data are expressed as percentage of the 
maximum degree of cell death (incubation of cells for 2 h with 0.01% of BAK); they represent the mean ± standard error of the mean of at least 3 experiments 
performed in triplicate. **p < 0.01 vs Veh; ***p < 0.001 vs Veh; Veh = vehicle, EDTA = disodium edetate, BAK = benzalkonium chloride, D-Panthenol =
Dexpanthenol. 
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effect of Keratosept on cultured conjunctival and corneal epithelial cells 
up to now. Concerning its components, The Cosmetic Ingredient Review 
Expert Panel (2007) reported no ocular signs of irritations in rabbits 
after instillation of hexamidine diisethionate 0.05% in aqueous solution. 
PHMB and hexamidine diisethionate toxicity on corneal epithelial cells 
has been evaluated in few in vitro studies: Shi et al. (2018) reported a 
reduction in cell proliferation at a maximum concentration of 0.02% 
PHMB and of 0.1% hexamidine. Nevertheless, they used different cell 
lines and they dissolved the drugs in a culture cell medium: therefore, 
their results are not directly comparable to our study. Yanai et al. 
(2006), using a colorimetric method, showed, in cultured human 
corneal epithelial cells, a low cytotoxicity of PHMB 0.0001% (1 part per 
million), which increased in a dose-dependent manner. 
In our in vitro studies, exposing human corneal epithelial cells to 
Keratosept or its components for different periods of time, we found 
significantly higher cytotoxicity and lower cell viability with Keratosept 
compared to the vehicle, only after 15 min. Regarding conjunctival 
epithelial cells the results were similar, with a significant reduction in 
cell viability after 10 min with Keratosept, and after 15 min with some 
components such as hexamidine, and no increase of cytotoxicity 
compared to the vehicle in the whole observation period. 
These results need to be confirmed by in vivo studies, as the ocular 
surface system is very different from our experimental setting for various 
reasons: for example, in a healthy eye the concentration of solutions 
instilled on the ocular surface can be reduced due to dilution in tears, 
and the exposure time may be lower due to lacrimal turnover and 
blinking; moreover, in our experimental setting, the cells were exposed 
to Keratosept or its components alone, without the nourishment usually 
supplied by culture medium. Therefore, we tested Keratosept and its 
components at a 1:10 dilution for 15 min: both the conjunctival and 
corneal cells did not show any significant cytotoxicity or reduced 
viability compared to the vehicle. Moreover, in our experimental 
setting, D-panthenol and polyvinyl alcohol showed an increase in cell 
viability at 5 min in human conjunctival epithelial cells and accelerated 
Fig. 7. Phase-contrast micrographs (10X magnification) of wounded cultured human corneal epithelial cells (HCE-2). The wound of the control (left) healed after 48 
h (bottom left). In cultures exposed to polyvinyl alcohol 1.25% and D-panthenol 5% the gap was closed in 24 h (middle right). D-Panthenol = Dexpanthenol. 
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the gap closure between corneal epithelial cells. This is consistent with 
the wound-healing properties of D-panthenol reported in studies on 
human dermal fibroblasts (Weimann and Hermann, 1999) and skin 
wounds (Heise et al., 2012), which explain its wide use in dermatology 
(Proksch et al., 2017). Polyvinyl alcohol is a biocompatible polymer, 
often present in ophthalmic solutions as a viscosity-enhancing agent 
(Ávila-Salas et al., 2019). 
In conclusion, in our study Keratosept ophthalmic solution showed a 
good in vitro antimicrobial activity on the bacterial strains most 
frequently responsible for ocular infections, including MRSA resistant to 
fluoroquinolones and aminoglycosides; however, Pseudomonas aerugi-
nosa, if grown on solid agar medium, appeared to be not susceptible. 
Moreover, Keratosept showed low cytotoxicity on cultured corneal and 
conjunctival epithelial cells. 
However, further in vitro studies are necessary to assess more pre-
cisely the antimicrobial efficacy of Keratosept ophthalmic solution, even 
on bacterial biofilms, and to evaluate the clinical antimicrobial efficacy 
on ocular surface infections; moreover, the tolerability of Keratosept 
needs to be confirmed in clinical studies. It could be interesting to 
compare, with the same experimental settings, the antimicrobial effi-
cacy and the cytotoxicity of different antiseptic-containing ophthalmic 
solutions. 
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